Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple sclerosis
Biotech
Lower dose of Tiziana CD3 drug hits MS goal, unlike higher dose
Tiziana’s intranasal drug hit dual endpoints of a study in a form of MS, but the win was marred by the higher dose missing a neuroinflammation goal.
James Waldron
Nov 2, 2026 8:37am
Roche builds blockbuster case in MS as FDA decision approaches
Oct 21, 2026 9:30am
Roche unpacks death imbalance in multiple sclerosis ph. 3 trials
Apr 21, 2026 7:15pm
Roche reports pivotal MS win, but deaths add to safety questions
Mar 2, 2026 6:00am
Novartis jettisons ph. 1 cancer candidate after 0% efficacy
Feb 19, 2026 2:45pm
Roche unveils data behind BTK inhibitor's phase 3 MS win
Feb 9, 2026 7:00am